BizDateUp Acquires 5.88% Stake in IOTA Diagnostic to Expand At-Home Testing Portfolio

The transaction strengthens BizDateUp’s exposure to preventive healthcare, women’s health, and patient-centric diagnostics emerging from India’s health technology ecosystem.

Mumbai-based BizDateUp has acquired a 5.88% stake in IOTA Diagnostic, a medical technology startup developing non-invasive, at-home diagnostic solutions. The investment amount was not disclosed. The transaction strengthens BizDateUp’s exposure to preventive healthcare, women’s health, and patient-centric diagnostics emerging from India’s health technology ecosystem.

IOTA Diagnostic is focused on shifting diagnostic testing away from hospital-dependent models toward home-based and self-administered solutions. Central to its portfolio is M-Strip™, a patented cervical cancer screening test that uses menstrual blood for do-it-yourself sampling. The solution is designed to address access, discomfort, and participation challenges commonly associated with conventional Pap smears and clinician-administered HPV tests.

According to the company, M-Strip™ has received approval from the Central Drugs Standard Control Organisation (CDSCO) and is supported by clinical validation and utility patent protection. The test allows sample collection at home without the need for clinical visits, positioning it as an alternative screening option for cervical cancer, particularly in low-access and underserved settings.

In addition to M-Strip™, IOTA Diagnostic is developing a broader diagnostics platform built around its BioSampler™ technology. The system enables the collection and transportation of blood and other biofluids without requiring cold-chain logistics or specialized phlebotomy services. The platform is intended to support remote diagnostics and decentralized testing, especially in regions with limited healthcare infrastructure.

BizDateUp stated that, beyond capital, it will provide strategic support to IOTA Diagnostic across regulatory planning, product development, manufacturing scale-up, and partnerships. The firm will also assist the company’s efforts to advance its regulatory roadmap, including preparation for US Food and Drug Administration approval, and facilitate access to global healthcare advisors.

In the near term, IOTA Diagnostic plans to expand its go-to-market strategy through a mix of direct-to-consumer channels, institutional tie-ups, and collaborations with hospitals, laboratories, and public health programs. The company also aims to extend its research and development efforts to add multiple diagnostic applications to its platform, while strengthening academic and clinical partnerships.

Stay tuned for more such updates on Digital Health News